Literature DB >> 11899034

A retrospective study of 19 cases of canine myelofibrosis.

Douglas J Weiss1, Stephanie A Smith.   

Abstract

Nineteen cases of myelofibrosis were identified among 456 canine bone marrow specimens submitted for analysis. Myelofibrosis was classified as primary in I dog and as secondary in 18 dogs. Clinical conditions associated with secondary myelofibrosis included immune-mediated hemolytic anemia (n = 5), neoplasia (n = 4), and long-term drug treatment (n = 4). Drugs administered included phenobarbital, phenytoin, phenylbutazone, and colchicine. Bone marrow necrosis was observed in 5 dogs. Eight dogs were treated with immunosuppressive doses of prednisolone, and 3 were treated with erythropoietin. Half of the dogs with secondary myelofibrosis recovered from their cytopenias and were alive from 4 months to 5 years after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11899034     DOI: 10.1892/0891-6640(2002)016<0174:arsoco>2.3.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  4 in total

1.  Suspected phenobarbital-induced pancytopenia in a cat.

Authors:  Maria Lyraki; Helen Wilson
Journal:  JFMS Open Rep       Date:  2020-05-27

2.  Targeted sequencing of candidate gene regions for myelofibrosis in dogs.

Authors:  Amelia G Campbell; Davis M Seelig; Joan D Beckman; Katie M Minor; Daniel A Heinrich; Steven G Friedenberg; Jaime F Modiano; Eva Furrow
Journal:  J Vet Intern Med       Date:  2022-07-11       Impact factor: 3.175

Review 3.  Antiepileptic drugs' tolerability and safety--a systematic review and meta-analysis of adverse effects in dogs.

Authors:  Marios Charalambous; Sara K Shivapour; David C Brodbelt; Holger A Volk
Journal:  BMC Vet Res       Date:  2016-05-21       Impact factor: 2.741

4.  Breed predispositions, clinical findings, and prognostic factors for death in dogs with nonregenerative immune-mediated anemia.

Authors:  Vanessa L Woolhead; Balazs Szladovits; Antonia Chan; James W Swann; Barbara Glanemann
Journal:  J Vet Intern Med       Date:  2020-12-08       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.